Sulfonamides Revisited, With an Emphasis on Dapsone

The sulfonamide moiety is a remarkable structure giving rise to diverse drugs in arious therapeutic areas such as antibiotics, antidiabetics, diuretics and anti-inflammatory agents. In regards to antibiotics, sulfonamides are in common use as antifungals (P. jiroveci), antiparasitics (toxoplasmosis, cyclospora, isospora, Continue reading Sulfonamides Revisited, With an Emphasis on Dapsone

A Patch? YES – A Fix? NO: This Emperor Has No Clothes

The NIH Department of HHS released its Final Rule on “Clinical Trials Registration and Results Information Submission” [1]. This Rule is meant to address frustrating maintenance and compliance issues in the ClinicalTrials.gov database, especially the results reporting section which has Continue reading A Patch? YES – A Fix? NO: This Emperor Has No Clothes

Timely New Information on Next-Generation Tetracyclines – Part 1: Omadacycline and Cardiac AEs

Several interesting articles appeared recently which shed light on the efficacy of eravacycline and the safety of omadacycline, both in Phase 3 and both in a head-to-head race to the market.  Well, the term ‘race’ is bit of a stretch as both Continue reading Timely New Information on Next-Generation Tetracyclines – Part 1: Omadacycline and Cardiac AEs

Solithromycin CAP Study:  Cap the Details (in the Publication)

In a recent publication, the results of a large Phase 3 trial comparing solithromycin with moxifloxacin in the treatment of CAP are presented [1]. As this was a global registration trial, we should refer to the indication as CABP, the current Continue reading Solithromycin CAP Study:  Cap the Details (in the Publication)

Quo Vadis, CDI Drugs?

There are only 3 CDI drugs in wider clinical use: vancomycin, metronidazole, and fidaxomicin. They are from totally different classes and have almost nothing in common except for proven efficacy in C. difficile infection (CDI). Like vancomycin, the entire group Continue reading Quo Vadis, CDI Drugs?

The Brave New World of Infectious Diseases

Coming back from ECCMID, one gets the impression that we are moving towards an era in which we can diagnose everything but treat nothing. A late breaker session on colistin resistance provided much detail data on the situation in the EU. As Continue reading The Brave New World of Infectious Diseases

Sherlock Holmes and Dr. Watson Reflecting on Recent Trouble in Microbe-Land

BREAKING NEWS – EARLY PRESS RELEASE APP News – April 1st   2016 Sherlock Holmes:  Well, I am excited about taking on the case of yet another frightening new microbe… Dr. Watson:  Yes, it is a particularly virulent bug, no treatment Continue reading Sherlock Holmes and Dr. Watson Reflecting on Recent Trouble in Microbe-Land

The Cresemba Candidemia Gamble – Rien Ne Va Plus

Isavuconazole is a potent triazole; like Voriconazole, it has garnered an indication for invasive aspergillosis. However, it failed where other azole antifungals succeeded: in a pivotal trial, not yet published, the drug was inferior to Caspofungin in the treatment of Continue reading The Cresemba Candidemia Gamble – Rien Ne Va Plus

Overcoming Antimicrobial Resistance – A European Report Recommends Deja-Vu Action

Sometimes one comes across a particularly well-written policy document which summarizes the status quo of antimicrobial resistance by connecting and synthesizing data from all kinds of sources into a coherent framework. The 2015 OECD Report on Antimicrobial Resistance in G7 Continue reading Overcoming Antimicrobial Resistance – A European Report Recommends Deja-Vu Action

Recent Sepsis Literature

SIRS, sepsis, severe sepsis, septic shock is a continuum, a crescendo of signs and symptoms associated with an infection uncontrolled by host responses. An avalanche or cascade of seemingly unstoppable events occurs often in a matter of hours which has Continue reading Recent Sepsis Literature

IV Fosfomycin To The Rescue – And To a Place Near You

A recent letter to the Editor by Simkins et al. is worth reviewing [1]. The authors describe the complicated course of a patient who suffered graft rejection after liver transplantation, received broad-spectrum antibiotics during prolonged hospitalization and eventually had a Continue reading IV Fosfomycin To The Rescue – And To a Place Near You

Brincidofovir – Another Drug Fails in Phase 3

It is sad to see a pivotal trial fail, and you have to wonder why we recently had several such late-stage ‘mishaps’. Take Tetraphase’s eravacycline which failed in a Phase 3 cUTI trial. We have analyzed this drug’s failure in earlier Continue reading Brincidofovir – Another Drug Fails in Phase 3

The 10 x ’20 Goal – Are We On Track?

In the last decade (2000-2010), we saw the number of new antibiotic approvals drop successively each year; FDA changed the rules of the approval process without providing public guidance; many antibiotic companies fled the therapeutic area; investments were redirected to Continue reading The 10 x ’20 Goal – Are We On Track?

Mister S. Goes To Washington

Let’s just assume that Mr. Martin Shkrely had provided full testimony at the Congressional hearing, this is what it might have said: Read my lips: NO MORE REBATES ! Link to this post!

Moving Towards Greater Transparency – One Step At A Time, Inexorably

Sharing trial data has been a controversial topic for quite a while. Recently the editors of major medical journals decided to take a stand. They will make access to trial source data a requirement, as a condition of publication, arguing that Continue reading Moving Towards Greater Transparency – One Step At A Time, Inexorably